The FDA has given mobocertinib expedited approval for metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations

September 2021: The FDA granted accelerated approval to mobocertinib (Exkivity, Takeda Pharmaceuticals, Inc.) for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have EGFR exon 20 insertio..

KRAS G12C, KRAS RGQ PCR kit, RAS GTPase, sotorasib

Sotorasib receives accelerated approval from the FDA for KRAS G12C mutant NSCLC

August 2021: The FDA granted accelerated approval to sotorasib (LumakrasTM, Amgen, Inc.), a RAS GTPase family inhibitor, for adult patients with KRAS G12C mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) w..

ALK, B7461006, crizotinib, Lorbrena, lorlatinib, NCT03052608, Pfizer, Ventana ALK, Ventana Medical Systems

Lorlatinib has been approved by the FDA for the treatment of metastatic ALK-positive NSCLC.

August 2021: Lorlatinib (Lorbrena, Pfizer Inc.) received regular FDA approval for patients with metastatic non-small cell lung cancer (NSCLC) whose tumours are anaplastic lymphoma kinase (ALK)-positive, as determined by an FDA-app..

anaplastic lymphoma kinase, B7461006, CDx Assay, Food and Drug Administration, Lorbrena, lorlatinib, NCT03052608, NSCLC, Pfizer, Ventana ALK, Ventana Medical Systems

Lorlatinib has been approved by the FDA for the treatment of metastatic ALK-positive NSCLC

August 2021: Lorlatinib (Lorbrena, Pfizer Inc.) received regular FDA approval for patients with metastatic non-small cell lung cancer (NSCLC) whose tumours are anaplastic lymphoma kinase (ALK)-positive, as determined by an FDA-app..

cemiplimab-rwlc, EGFR, FDA, Food and Drug Administration, NCT03088540, NSCLC, PD-L1 expression

Cemiplimab-rwlc has been approved by the FDA for non-small cell lung cancer with high PD-L1 expression

August 2021: The FDA approved cemiplimab-rwlc (Libtayo, Regeneron Pharmaceuticals, Inc.) for the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) (locally advanced who are not candidates for surgic..

FDA, KRAS G12C, Lumakras, NSCLC, sotorasib

The FDA has approved the first targeted therapy for a lung cancer mutation that was previously thought to be drug-resistant

August 20, 2021: Recently in May, 2021 Lumakras (sotorasib) was approved by the US Food and Drug Administration as the first treatment for adult patients with non-small cell lung cancer who have undergone at least one prior system..

Cigarettes

More than 12% of newly diagnosed lung cancer patients newer smoked cigarettes – study suggests

July 7th 2021 : Tobacco smoking is the leading cause of lung cancer, accounting for over 80% of all fatalities from the disease. People who do not smoke, however, are also susceptible to lung cancer. According to a new study, arou..

Drug resistance in non-small cell lung cancer

What to do about drug resistance of non-small cell lung cancer targeted drugs, you want to know hereLung cancer is the cancer with the highest morbidity and mortality in China. About 1.6 million people die of this disease each yea..

PD-1 and PD-l1 treatment of lung cancer

Lung cancer immunotherapy, lung cancer immunotherapy, lung cancer PD-1 treatment, and lung cancer PD-L1 treatment are all you want to know. In the past two years, immune checkpoint inhibitors have undoubtedly been one of the most..

Brigatinib for ALK-positive crizotinib resistant non-small cell lung cancer

Dong-Wan Kim scholars from the Seoul National University Hospital in South Korea will give an oral report on the special meeting of metastatic non-small cell lung cancer at the 52nd Annual Meeting of the American Society of Oncolo..